{"id":"potassium-acetate","rwe":[{"pmid":"41874354","year":"2026","title":"Atomic origins of electrochemical stability in acetate-based dual-cation water-in-salt electrolytes.","finding":"","journal":"The Journal of chemical physics","studyType":"Clinical Study"},{"pmid":"41618149","year":"2026","title":"Mitigating grapevine esca disease: an innovative integrated management strategy to reduce incidence and severity by enhancing plant physiology and defence mechanisms.","finding":"","journal":"BMC plant biology","studyType":"Clinical Study"},{"pmid":"41613577","year":"2026","title":"Sustainable and Highly Efficient Synthesis of Reactive Diluents from Renewable Sources for Property-Enhancing Purposes in Glass-Containing Material Composites.","finding":"","journal":"Precision chemistry","studyType":"Clinical Study"},{"pmid":"41472537","year":"2026","title":"Phase Transition Behavior of Acetate Electrolyte and Its Application in Aqueous Sodium-Ion Batteries.","finding":"","journal":"Langmuir : the ACS journal of surfaces and colloids","studyType":"Clinical Study"},{"pmid":"41415934","year":"2025","title":"Pediatric Diabetic Ketoacidosis: Comparing Outcomes of Potassium Acetate Versus Potassium Chloride Using the Two-Bag System.","finding":"","journal":"The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG","studyType":"Clinical Study"}],"_fda":{"id":"ea996741-0733-42bc-9ea6-4392cbfb2c37","set_id":"2f069f41-903a-4a57-b566-eda5c44367d8","openfda":{"upc":["0365219512028"],"unii":["M911911U02"],"route":["INTRAVENOUS"],"rxcui":["237381"],"spl_id":["ea996741-0733-42bc-9ea6-4392cbfb2c37"],"brand_name":["Potassium Acetate"],"spl_set_id":["2f069f41-903a-4a57-b566-eda5c44367d8"],"package_ndc":["65219-512-02","65219-512-50"],"product_ndc":["65219-512"],"generic_name":["POTASSIUM ACETATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["POTASSIUM ACETATE"],"manufacturer_name":["Fresenius Kabi USA, LLC"],"application_number":["ANDA217515"],"is_original_packager":[true]},"version":"1","warnings":["WARNINGS Potassium Acetate Injection (2 mEq/mL) must be diluted before use. To avoid potassium intoxication, infuse potassium-containing solutions slowly. Potassium replacement therapy should be monitored whenever possible by continuous or serial electrocardiography (ECG). Serum potassium levels are not necessarily dependable indicators of tissue potassium levels. Solutions which contain potassium ions should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present. In patients with diminished renal function, administration of solutions containing potassium ions may result in potassium retention. Solutions containing acetate ions should be used with great care in patients with metabolic or respiratory alkalosis. Acetate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency. WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration."],"pregnancy":["Pregnancy Animal reproduction studies have not been conducted with potassium acetate. It is also not known whether potassium acetate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium acetate should be given to a pregnant woman only if clearly needed."],"overdosage":["OVERDOSAGE In the event of overdosage, discontinue infusion containing potassium acetate immediately and institute corrective therapy as indicated to reduce elevated serum potassium levels and restore acid-base balance if necessary. (See WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS .)"],"description":["DESCRIPTION Potassium Acetate Injection, USP (2 mEq/mL) is a sterile, nonpyrogenic, concentrated solution of potassium acetate in water for injection. The solution is administered after dilution by the intravenous route as an electrolyte replenisher. It must not be administered undiluted. Each mL contains 196 mg of potassium acetate which provides 2 mEq each of potassium (K + ) and acetate (CH 3 COO − ). The solution may contain acetic acid for pH adjustment. The pH is 6.2 (range: 5.5 to 8.0). The osmolar concentration is 4 mOsmol/mL (calc.); specific gravity is 1.089. The Pharmacy Bulk Package is a sterile dosage which contains multiple single doses for use only in a pharmacy bulk admixture program. The solution is intended as an alternative to potassium chloride to provide potassium ion (K + ) for addition to large volume infusion fluids for intravenous use. Potassium Acetate, USP is chemically designated CH 3 COOK, and is comprised of colorless crystals or a white crystalline powder that is very soluble in water. The Pharmacy Bulk Package is designed for use with manual, gravity flow operations and automated compounding devices for preparing sterile parenteral nutrient admixtures. The Pharmacy Bulk Package contains no bacteriostat, antimicrobial agent, or added buffer. Multiple single doses may be dispensed during continual aliquoting operations."],"precautions":["PRECAUTIONS Do not administer unless solution is clear and seal is intact. Discard unused portion. Potassium replacement therapy should be guided primarily by ECG monitoring and secondarily by the serum potassium level. High plasma concentrations of potassium may cause death by cardiac depression, arrhythmias or arrest. Use with caution in the presence of cardiac disease, particularly in digitalized patients or in the presence of renal disease. Solutions containing acetate ion should be used with caution as excess administration may result in metabolic alkalosis. Pregnancy Animal reproduction studies have not been conducted with potassium acetate. It is also not known whether potassium acetate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Potassium acetate should be given to a pregnant woman only if clearly needed. Pediatric Use: The safety and effectiveness of potassium acetate have been established in pediatric patients. Geriatric Use: An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Potassium ions are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"how_supplied":["HOW SUPPLIED Potassium Acetate Injection, USP is a Pharmacy Bulk Package which provides multiple single doses for continuous admixture compounding procedures is supplied as follows: Product Code Unit of Sale Strength Each 510150 NDC 65219-512-50 Unit of 25 100 mEq/50 mL (2 mEq/mL) NDC 65219-512-02 50 mL Pharmacy Bulk Package Fliptop Vial Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] The container closure is not made with natural rubber latex. www.fresenius-kabi.com/us 451831 Issued: August 2024 Fresenius Kabi Logo"],"geriatric_use":["Geriatric Use: An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Potassium ions are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"pediatric_use":["Pediatric Use: The safety and effectiveness of potassium acetate have been established in pediatric patients."],"effective_time":"20241206","adverse_reactions":["ADVERSE REACTIONS Adverse reactions involve the possibility of potassium intoxication. The signs and symptoms of potassium intoxication include paresthesias of the extremities, flaccid paralysis, listlessness, mental confusion, weakness and heaviness of the legs, hypotension, cardiac arrhythmias, heart block, electrocardiographic abnormalities such as disappearance of P waves, spreading and slurring of the QRS complex with development of a biphasic curve and cardiac arrest. (See WARNINGS and PRECAUTIONS .) To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."],"contraindications":["CONTRAINDICATIONS Potassium administration is contraindicated in patients with severe renal insufficiency or adrenal insufficiency and in diseases where high potassium levels may be encountered."],"how_supplied_table":["
Product Code
Unit of Sale
Strength
Each
510150
NDC 65219-512-50 Unit of 25
100 mEq/50 mL (2 mEq/mL)
NDC 65219-512-02 50 mL Pharmacy Bulk Package Fliptop Vial
"],"clinical_pharmacology":["CLINICAL PHARMACOLOGY As the principal cation of the intracellular fluid, potassium plays an important role in fluid and electrolyte balance. The normal potassium concentration in the intracellular fluid compartment is about 160 mEq/liter. The normal serum potassium range is 3.5 to 5.0 mEq/liter. The kidney normally regulates potassium balance but does not conserve potassium as well or as promptly as it conserves sodium. The daily turnover of potassium in the normal adult averages 50 to 150 mEq (milliequivalents) and represents 1.5 to 5% of the total potassium content of the body. Acetate (CH 3 COO − ), a source of hydrogen ion acceptors, is an alternate source of bicarbonate (HCO 3 − ) by metabolic conversion in the liver. This has been shown to proceed readily, even in the presence of severe liver disease."],"indications_and_usage":["INDICATIONS AND USAGE Potassium Acetate Injection (2 mEq/mL) is indicated as a source of potassium, for the addition to large volume intravenous fluids, to prevent or correct hypokalemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions."],"spl_unclassified_section":["100 mEq/50 mL (2 mEq/mL) (2 mEq K + /mL and 2 mEq CH 3 COO − /mL) Pharmacy Bulk Package- Not for Direct Infusion. CONCENTRATED SOLUTION - FOR INTRAVENOUS USE ONLY AFTER DILUTION AND THOROUGH MIXING. Plastic Vial Rx only"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Potassium Acetate Injection, USP (2 mEq/mL) in the Pharmacy Bulk Package is designed for use with manual, gravity flow operations and automated compounding devices for preparing sterile nutrient admixtures. Potassium Acetate Injection, USP (2 mEq/mL) is administered intravenously only after dilution in a larger volume of fluid . The dose and rate of administration are dependent upon the individual needs of the patient. ECG and serum potassium should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of milliequivalents (mEq) of potassium (K + ) with an equal number of milliequivalents of acetate (CH 3 COO − ). Maximum infusion rate: The infusion rate should not exceed 1 mEq/kg/hr. Normal daily requirements: Newborn: 2-6 mEq/kg/24 hr. Children: 2-3 mEq/kg/24 hr. Adult: 40-80 mEq/24 hr. Intraosseous infusion can be an alternate route for drug administration when intravenous access is not readily available. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (See PRECAUTIONS .) Directions for Dispensing From Pharmacy Bulk Package The Pharmacy Bulk Package is for use in the Pharmacy Admixtures Service only. A single entry through the vial closure should be made with a sterile dispensing set or transfer device. Transfer individual doses to appropriate intravenous infusion solutions. Use of a syringe with needle is not recommended as it may cause leakage and multiple entries will increase the potential of microbial and particulate contamination. The above process should be carried out under a laminar flow hood using aseptic technique. Discard any unused portion within 4 hours after initial closure entry."],"spl_product_data_elements":["Potassium Acetate POTASSIUM ACETATE POTASSIUM ACETATE POTASSIUM CATION WATER ACETIC ACID"],"spl_unclassified_section_table":["
Pharmacy Bulk Package- Not for Direct Infusion.
"],"dosage_and_administration_table":["
Newborn:
2-6 mEq/kg/24 hr.
Children:
2-3 mEq/kg/24 hr.
Adult:
40-80 mEq/24 hr.
"],"package_label_principal_display_panel":["Package Label - Principal Display Panel – Potassium Acetate Injection, USP 50 mL Vial Label NDC 65219-512-02 Potassium Acetate Injection, USP K+ 100 mEq/50 mL (2 mEq/mL) Pharmacy Bulk Package-Not for Direct Infusion CAUTION: MUST BE DILUTED. FOR INTRAVENOUS USE* 50 mL Rx only Package Label - Principal Display Panel – Potassium Acetate Injection, USP 50 mL Vial Label","Package Label - Principal Display Panel – Potassium Acetate Injection, USP 50 mL Tray Label NDC 65219-512-50 Contains 25 of NDC 65219-512-02 Potassium Acetate Injection, USP 100 mEq/50 mL (2 mEq/mL) Pharmacy Bulk Package-Not for Direct Infusion CAUTION: MUST BE DILUTED. FOR INTRAVENOUS USE* 50 mL Rx only Package Label - Principal Display Panel – Potassium Acetate Injection, USP 50 mL Tray Label"]},"tags":[{"label":"potassium acetate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"B05XA17","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Hypokalemia","category":"indication"},{"label":"Hypokalemia Prevention","category":"indication"},{"label":"Hospira","category":"company"},{"label":"Approved 1970s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"139 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"130 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"128 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"120 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"102 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"100 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"97 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"90 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"87 reports"},{"date":"","signal":"ARTHRALGIA","source":"FDA FAERS","actionTaken":"73 reports"}],"drugInteractions":[{"url":"/drug/quinapril","drug":"quinapril","action":"Monitor closely","effect":"May interact with Quinapril","source":"DrugCentral","drugSlug":"quinapril"},{"url":"/drug/ramipril","drug":"ramipril","action":"Monitor closely","effect":"May interact with Ramipril","source":"DrugCentral","drugSlug":"ramipril"},{"url":"/drug/spironolactone","drug":"spironolactone","action":"Monitor closely","effect":"May interact with Spironolactone","source":"DrugCentral","drugSlug":"spironolactone"},{"url":"/drug/triamterene","drug":"triamterene","action":"Monitor closely","effect":"May interact with Triamterene","source":"DrugCentral","drugSlug":"triamterene"}],"commonSideEffects":[{"effect":"Cardiac arrest","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Cardiac arrhythmias","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Heart block","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Electrocardiographic abnormalities","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Muscular or respiratory paralysis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Areflexia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Paresthesias of the extremities","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Mental confusion","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Weakness","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Hypotension","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Respiratory depression","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Circulatory collapse","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Depression of cardiac and central nervous system function","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Abdominal pain","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Nausea","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Vomiting","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Edema","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Exacerbation of congestive heart failure","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Flushing","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Sweating","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Tachycardia","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Hypertension","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Hyperirritability","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Psychotic behavior","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Cramps","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Convulsions","drugRate":"≥5%","severity":"mild","_validated":true}],"specialPopulations":{"Pregnancy":"Hyperlyte(R) CR should be given to pregnant woman only if clearly needed.","Geriatric use":"Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.","Paediatric use":"The safety and effectiveness of potassium acetate have been established in pediatric patients.","Hepatic impairment":"An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Potassium Acetate","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:37:12.611210+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:37:18.251504+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-19T23:37:11.727109+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Potassium Acetate","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:37:19.135757+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:03.725860+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:03.725887+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T23:37:21.479766+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201058/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:37:20.430312+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA217515","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T23:37:03.725891+00:00"}},"allNames":["potassium acetate","acetic acid, potassium salt"],"offLabel":[],"synonyms":["potassium acetate","acetic acid, potassium salt"],"timeline":[{"date":"1971-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from B BRAUN to Hospira"},{"date":"1971-09-24","type":"positive","source":"DrugCentral","milestone":"FDA approval (B Braun)"},{"date":"2015-12-29","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Potassium Acetate is a small molecule drug originally developed by B BRAUN and currently owned by Hospira. It is FDA-approved for the treatment of hypokalemia and prevention of hypokalemia. The commercial status of Potassium Acetate is off-patent, with two generic manufacturers available. Key safety considerations include the potential for hyperkalemia, a condition characterized by elevated potassium levels in the blood. As an off-patent medication, Potassium Acetate is widely available and used to treat hypokalemia.","brandName":"Potassium Acetate","ecosystem":[{"indication":"Hypokalemia","otherDrugs":[{"name":"aspartic acid","slug":"aspartic-acid","company":""},{"name":"calcium chloride","slug":"calcium-chloride","company":"Baxter Hlthcare"},{"name":"potassium chloride","slug":"potassium-chloride","company":"Hospira"},{"name":"potassium citrate","slug":"potassium-citrate","company":"Mission Pharma"}],"globalPrevalence":null},{"indication":"Hypokalemia Prevention","otherDrugs":[{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"aspartic acid","slug":"aspartic-acid","company":""},{"name":"calcium chloride","slug":"calcium-chloride","company":"Baxter Hlthcare"},{"name":"potassium chloride","slug":"potassium-chloride","company":"Hospira"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"potassium acetate","explanation":"","oneSentence":"","technicalDetail":"Potassium Acetate is a potassium salt that is rapidly absorbed into the bloodstream, increasing serum potassium concentrations and helping to correct hypokalemia."},"commercial":{"launchDate":"1971","_launchSource":"DrugCentral (FDA 1971-09-24, B BRAUN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4217","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Potassium%20Acetate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Potassium Acetate","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T01:57:26.913893","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:23.552724+00:00","fieldsConflicting":14,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"potassium chloride","drugSlug":"potassium-chloride","fdaApproval":"1965-12-16","patentExpiry":"Mar 7, 2039","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sodium bicarbonate","drugSlug":"sodium-bicarbonate","fdaApproval":"1981-10-28","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sodium chloride","drugSlug":"sodium-chloride","fdaApproval":"1965-12-16","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ammonium chloride","drugSlug":"ammonium-chloride","fdaApproval":"1978-10-13","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"magnesium sulfate","drugSlug":"magnesium-sulfate","fdaApproval":"1981-10-06","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"calcium chloride","drugSlug":"calcium-chloride","fdaApproval":"1971-03-22","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sodium acetate","drugSlug":"sodium-acetate","fdaApproval":"1983-05-04","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sodium phosphate","drugSlug":"sodium-phosphate","fdaApproval":"1983-05-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"magnesium chloride","drugSlug":"magnesium-chloride","fdaApproval":"1975-08-13","relationship":"same-class"},{"drugName":"zinc chloride","drugSlug":"zinc-chloride","fdaApproval":"1986-06-26","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sodium glycerophosphate","drugSlug":"sodium-glycerophosphate","fdaApproval":"2014-08-25","relationship":"same-class"},{"drugName":"potassium lactate","drugSlug":"potassium-lactate","fdaApproval":"1986-05-08","relationship":"same-class"},{"drugName":"zinc sulfate","drugSlug":"zinc-sulfate","fdaApproval":"1987-05-05","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"potassium acetate","indications":{"approved":[{"name":"Hypokalemia","source":"DrugCentral","snomedId":43339004,"regulator":"FDA","eligibility":"patients with restricted or no oral intake"},{"name":"Hypokalemia Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"patients with restricted or no oral intake"}],"offLabel":[],"pipeline":[]},"currentOwner":"Hospira","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"potassium-chloride","brandName":"potassium chloride","genericName":"potassium chloride","approvalYear":"1965","relationship":"same-class"},{"drugId":"sodium-bicarbonate","brandName":"sodium bicarbonate","genericName":"sodium bicarbonate","approvalYear":"1981","relationship":"same-class"},{"drugId":"sodium-chloride","brandName":"sodium chloride","genericName":"sodium chloride","approvalYear":"1965","relationship":"same-class"},{"drugId":"ammonium-chloride","brandName":"ammonium chloride","genericName":"ammonium chloride","approvalYear":"1978","relationship":"same-class"},{"drugId":"magnesium-sulfate","brandName":"magnesium sulfate","genericName":"magnesium sulfate","approvalYear":"1981","relationship":"same-class"},{"drugId":"calcium-chloride","brandName":"calcium chloride","genericName":"calcium chloride","approvalYear":"1971","relationship":"same-class"},{"drugId":"sodium-acetate","brandName":"sodium acetate","genericName":"sodium acetate","approvalYear":"1983","relationship":"same-class"},{"drugId":"sodium-phosphate","brandName":"sodium phosphate","genericName":"sodium phosphate","approvalYear":"1983","relationship":"same-class"},{"drugId":"magnesium-chloride","brandName":"magnesium chloride","genericName":"magnesium chloride","approvalYear":"1975","relationship":"same-class"},{"drugId":"zinc-chloride","brandName":"zinc chloride","genericName":"zinc chloride","approvalYear":"1986","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04102371","phase":"PHASE3","title":"Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2020-08-25","conditions":["Shock","Septic"],"enrollment":9041,"completionDate":"2026-01-31"},{"nctId":"NCT06414330","phase":"PHASE3","title":"Ringer Acetate Based Modified Del Nido Cardioplegia Solution Versus HTK Solution Cardioplegia Solution in Cardiac Surgery","status":"COMPLETED","sponsor":"Assiut University","startDate":"2024-06-01","conditions":["Cardiac Ischemia"],"enrollment":124,"completionDate":"2025-12-01"},{"nctId":"NCT07239713","phase":"NA","title":"Clinical Effects of Ringers Lactate Versus Sterofundin/ Plasmalyte Solution in Patients With Sepsis","status":"RECRUITING","sponsor":"CMH Lahore Medical College and Institute of Dentistry","startDate":"2025-11-15","conditions":["Post Abdominal Surgery","Sepsis Abdominal"],"enrollment":82,"completionDate":"2026-06-15"},{"nctId":"NCT07163936","phase":"NA","title":"Analysis of the Influence of Dialysis Fluid Composition on Vascular Calcification in Patients With Chronic Kidney Disease Undergoing Hemodialysis","status":"NOT_YET_RECRUITING","sponsor":"Hospital Clinic of Barcelona","startDate":"2025-09-03","conditions":["Vascular Calcification","Hemodialysis","Cardiovascular Disease (CKD)"],"enrollment":80,"completionDate":"2026-09-06"},{"nctId":"NCT06911073","phase":"NA","title":"A Study to Evaluate a Postbiotic in Supporting Weight Loss and Metabolic Health","status":"RECRUITING","sponsor":"ResBiotic Nutrition, Inc.","startDate":"2025-05-02","conditions":["Obesity and Overweight"],"enrollment":80,"completionDate":"2025-12"},{"nctId":"NCT05682261","phase":"NA","title":"The Effect of Multiple Micronutrient Supplements in Reducing Anemia in Women of Reproductive Age","status":"COMPLETED","sponsor":"Ethiopian Public Health Institute","startDate":"2023-03-23","conditions":["Anemia"],"enrollment":265,"completionDate":"2023-10-17"},{"nctId":"NCT05708183","phase":"","title":"Healthy Mums, Healthy Babies: Multiple Micronutrient Supplementation in Ethiopia","status":"RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2023-01-01","conditions":["Birth Weight"],"enrollment":25620,"completionDate":"2025-08-31"},{"nctId":"NCT01013792","phase":"NA","title":"A Comparison of an Investigational Dressing to Tegaderm Matrix Wound Dressing in the Management of Diabetic Foot Ulcers","status":"TERMINATED","sponsor":"Solventum US LLC","startDate":"2009-11","conditions":["Foot Ulcer, Diabetic"],"enrollment":30,"completionDate":"2012-07"},{"nctId":"NCT06374823","phase":"PHASE4","title":"Multiple Electrolytes Injection (II) and Normal Saline on Hyperchloremia in Severe Hemorrhagic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Capital Medical University","startDate":"2024-05","conditions":["Critical Care","Hyperchloremia","Hemorrhagic Stroke"],"enrollment":342,"completionDate":"2026-12"},{"nctId":"NCT04586348","phase":"PHASE4","title":"Prenatal Iodine Supplementation and Early Childhood Neurodevelopment","status":"ACTIVE_NOT_RECRUITING","sponsor":"South Australian Health and Medical Research Institute","startDate":"2021-01-18","conditions":["Pregnancy Related","Neurodevelopmental Disorders","Nutrition Disorder, Fetal"],"enrollment":794,"completionDate":"2025-12"},{"nctId":"NCT06148662","phase":"PHASE4","title":"The Effect of Oral Sprays on Salivary pH","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2023-12-01","conditions":["Oral Health"],"enrollment":33,"completionDate":"2024-01-25"},{"nctId":"NCT06146712","phase":"NA","title":"A Single-Group Study to Examine the Efficacy of a Melatonin Lotion With Magnesium to Improve Sleep Quality and Quantity","status":"COMPLETED","sponsor":"Asutra","startDate":"2023-08-07","conditions":["Sleep"],"enrollment":35,"completionDate":"2023-10-02"},{"nctId":"NCT06076590","phase":"PHASE4","title":"Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2021-11-01","conditions":["Aneurysmal Subarachnoid Hemorrhage","Hyperchloremia"],"enrollment":60,"completionDate":"2023-05-31"},{"nctId":"NCT02019628","phase":"NA","title":"Enhanced Natural Killer Cell Activity and RBAC","status":"COMPLETED","sponsor":"University of Miami","startDate":"2009-11","conditions":["Family Member"],"enrollment":20,"completionDate":"2011-11"},{"nctId":"NCT05523115","phase":"NA","title":"An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits","status":"COMPLETED","sponsor":"Heights","startDate":"2022-06-15","conditions":["Anxiety","Stress","Memory Deficits","Cortisol Overproduction"],"enrollment":34,"completionDate":"2022-10-01"},{"nctId":"NCT04595942","phase":"PHASE3","title":"Midodrine and Fludrocortisone for Vasovagal Syncope","status":"UNKNOWN","sponsor":"Tehran Heart Center","startDate":"2020-11-19","conditions":["Syncope, Vasovagal"],"enrollment":1375,"completionDate":"2023-12"},{"nctId":"NCT04768465","phase":"","title":"Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2021-01-01","conditions":["Myasthenia Gravis"],"enrollment":160,"completionDate":"2024-10-31"},{"nctId":"NCT02956070","phase":"NA","title":"Anti-inflammatory Steroids in the Prevention of Tooth Sensitivity","status":"COMPLETED","sponsor":"Universidade Federal Fluminense","startDate":"2015-10","conditions":["Inflammation"],"enrollment":70,"completionDate":"2016-05"},{"nctId":"NCT02560519","phase":"PHASE4","title":"Albumin in Cardiac Surgery","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2017-03-21","conditions":["C.Surgical Procedure; Cardiac"],"enrollment":1386,"completionDate":"2020-11-04"},{"nctId":"NCT03054922","phase":"PHASE3","title":"Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables","status":"COMPLETED","sponsor":"Nationwide Children's Hospital","startDate":"2017-02-23","conditions":["Anesthesia"],"enrollment":59,"completionDate":"2018-09-30"},{"nctId":"NCT02157506","phase":"PHASE2","title":"A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2014-06-30","conditions":["Heart Failure","Decompensated Heart Failure","Acute Heart Failure"],"enrollment":70,"completionDate":"2015-07-31"},{"nctId":"NCT03611283","phase":"NA","title":"Topical Management of Xerostomia With Dry Mouth Products","status":"COMPLETED","sponsor":"Rosa María López-Pintor Muñoz","startDate":"2016-10-03","conditions":["Xerostomia","Sjogren's Syndrome"],"enrollment":28,"completionDate":"2017-11-30"},{"nctId":"NCT02668952","phase":"PHASE2","title":"Fluid Chloride and AKI in Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2016-01","conditions":["Acute Kidney Injury"],"enrollment":30,"completionDate":"2018-02"},{"nctId":"NCT02707549","phase":"PHASE2","title":"Fluid Therapy During Brain Tumor Resection in Children","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2015-08","conditions":["Brain Neoplasms"],"enrollment":53,"completionDate":"2017-06"},{"nctId":"NCT03230396","phase":"NA","title":"Vitamin Gum Pharmacokinetics","status":"COMPLETED","sponsor":"Penn State University","startDate":"2014-10-13","conditions":["Nutrient Pharmacokinetics"],"enrollment":15,"completionDate":"2015-07-01"},{"nctId":"NCT02848937","phase":"","title":"Calcium Mass Balance and Dialytic Efficiency of a New cITRate-containing and Acetate-free Dialysis flUidS: CITRUS Study","status":"UNKNOWN","sponsor":"Azienda Ospedaliera, Ospedale Civile di Legnano","startDate":"2013-03","conditions":["ESRD"],"enrollment":62,"completionDate":"2016-12"},{"nctId":"NCT02414555","phase":"PHASE4","title":"Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support","status":"TERMINATED","sponsor":"Medical University of Vienna","startDate":"2015-03","conditions":["Critical Illness"],"enrollment":60,"completionDate":"2016-03"},{"nctId":"NCT02034682","phase":"NA","title":"The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-01","conditions":["Microvascular Reactivity","Tissue Oxygen Saturation"],"enrollment":40,"completionDate":"2015-04"},{"nctId":"NCT01516138","phase":"PHASE2","title":"Benefits of GIK in Cardiac Surgery Patients","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2012-02","conditions":["Cardiac Surgery","Cardiopulmonary Bypass"],"enrollment":930,"completionDate":"2022-02"},{"nctId":"NCT00980733","phase":"PHASE3","title":"Efficacy of Micronutrient Fortified Yoghurt in School Children for Health Benefits","status":"UNKNOWN","sponsor":"Annamalai University","startDate":"2008-09","conditions":["Child Development","Cognitive Development","Morbidity","Physical Growth"],"enrollment":1325,"completionDate":"2010-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Potassium Acetate"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"NORMOSOL-M AND DEXTROSE"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Potassium Acetate"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Potassium Acetate"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"HyperlyteCR"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000145902","MMSL":"1780","NDDF":"000764","UNII":"M911911U02","VUID":"4017517","CHEBI":"CHEBI:32029","VANDF":"4017517","RXNORM":"54987","UMLSCUI":"C0137984","chemblId":"CHEMBL1201058","ChEMBL_ID":"CHEMBL1201058","KEGG_DRUG":"D01154","DRUGBANK_ID":"DB14498","PUBCHEM_CID":"517044","MESH_DESCRIPTOR_UI":"D019347"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","company":"B. Braun Medical Inc.","brandName":"HyperlyteCR","isOriginal":true,"marketingStatus":"UNAPPROVED DRUG OTHER"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1971-","companyName":"B Braun","relationship":"Original Developer"},{"period":"present","companyName":"Pfizer","relationship":"Current Owner"}],"publicationCount":549,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"B05XA17","allCodes":["B05XA17"]},"biosimilarFilings":[],"originalDeveloper":"B Braun","recentPublications":[{"date":"2026 Mar 28","pmid":"41874354","title":"Atomic origins of electrochemical stability in acetate-based dual-cation water-in-salt electrolytes.","journal":"The Journal of chemical physics"},{"date":"2026 Jan 30","pmid":"41618149","title":"Mitigating grapevine esca disease: an innovative integrated management strategy to reduce incidence and severity by enhancing plant physiology and defence mechanisms.","journal":"BMC plant biology"},{"date":"2026 Jan 26","pmid":"41613577","title":"Sustainable and Highly Efficient Synthesis of Reactive Diluents from Renewable Sources for Property-Enhancing Purposes in Glass-Containing Material Composites.","journal":"Precision chemistry"},{"date":"2026 Jan 13","pmid":"41472537","title":"Phase Transition Behavior of Acetate Electrolyte and Its Application in Aqueous Sodium-Ion Batteries.","journal":"Langmuir : the ACS journal of surfaces and colloids"},{"date":"2025 Dec","pmid":"41415934","title":"Pediatric Diabetic Ketoacidosis: Comparing Outcomes of Potassium Acetate Versus Potassium Chloride Using the Two-Bag System.","journal":"The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG"}],"companionDiagnostics":[],"genericManufacturers":2,"_genericFilersChecked":true,"genericManufacturerList":["Exela Pharma","Fresenius Kabi Usa"],"status":"approved","companyName":"Hospira","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1971","enrichmentLevel":3,"visitCount":9,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-08-30T00:00:00.000Z","mah":"OTSUKA ICU MEDCL","brand_name_local":null,"application_number":"NDA017610"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2001-02-16T00:00:00.000Z","mah":"HOSPIRA","brand_name_local":null,"application_number":"NDA018896"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-10-25T00:00:00.000Z","mah":"EXELA PHARMA","brand_name_local":null,"application_number":"ANDA206203"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-11-27T00:00:00.000Z","mah":"FRESENIUS KABI USA","brand_name_local":null,"application_number":"ANDA217515"},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:37:23.552724+00:00","fieldsConflicting":14,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}